Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Malaria drug combo shows promise against COVID-19 in early trial

NCT ID NCT04339426

Disease control Sponsor: HonorHealth Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combination of atovaquone (an anti-malarial) and azithromycin (an antibiotic) can clear the COVID-19 virus in infected adults. The study enrolls people at high risk for complications, such as those with moderate to severe illness. Participants receive the drugs for up to 10 days, and researchers measure how many achieve an undetectable viral load.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atovaquone and azithromycin
What this could lead to
If successful, this combination could offer a new treatment option to clear COVID-19 infection in high-risk patients.
What could go wrong
This is a very small, early-phase trial with only 3 participants, so results may not apply broadly. The drugs can cause gastrointestinal side effects and heart rhythm changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

3 people

The number who actually took part.

Started

Apr 2020

Finished

Feb 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 95 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and Female patients age 18 years or older * COVID-19 confirmed positive test results * High risk for complications including with Medium (5-6) or High (More than or equal to 7) NEWS score * Hematology criteria: ANC \>500 cells/mcl, HGB \>9 g/dl, Platelet count \>75,000/mcl * Metabolic criteria: Serum creatinine \<2.0 mg/dl or calculated creatinine clearance (using Cockcroft-Gault) \>30 ml/min, AST/ALT \<5x ULN AND Total Bilirubin WNL (for patients with Gilbert's disease, direct bilirubin \<ULN) Exclusion Criteria: * COVID-19 negative test result * Inability to adhere to study protocol requirements * Inability to provide informed consent * Other acute or chronic medical or psychiatric condition that in the judgment of the investigator would make the participant inappropriate to take part in the study * Pregnant and breastfeeding individuals * QTc interval greater than 470 msecs at baseline * History of hypersensitivity to atovaquone and/or azithromycin. * History of known intolerance to atovaquone and/or azithromycin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19

Contacts and locations

Locations

  • HonorHealth

    Scottsdale, Arizona, 85258, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.